Hepatoprotective drugs associated with a reduced risk of
in-hospital mortality
The use of hepatoprotective drugs in the patients with cumulative LBAI
tended to attenuate the risk of in-hospital mortality by 38% in the
univariate model (crude HR 0.62; 95% CI 0.41 to 0.96; figure 3f;
supplementary table 2) compared to their normal LB counterparts,
although this association was not significant after adjustment for
confounding risk factors such as age, sex, comorbidities, disease
severity, lymphocyte count, D-dimer, serum ferritin (adjusted HR 0.67;
95% CI 0.4 to 1.08).